Cell and Gene Outsourcing

  1. Accelerating Technology Diffusion In Cell And Gene Therapy 3/11/2026

    Unlike most other drugs, advanced therapies require complex, purpose-built supply chain networks. Making them requires cross-sector collaboration.

  2. Precision Control In Animal‑Free Raw Materials 3/10/2026

    Animal‑free raw materials offer adjustable attributes, controlled manufacturing, and consistent nutrient profiles, ensuring reliable performance and customizable solutions across multiple production processes.

  3. Consistency Engineered For Animal‑Free Bioprocessing 3/10/2026

    Animal‑free soy‑based materials provide consistent molecular weight profiles, stable mineral levels, and controlled manufacturing to ensure reliable, reproducible bioprocessing performance.

  4. Consistency You Can Trust in Animal‑Free Raw Materials 3/10/2026

    Animal‑free raw materials ensure reliable bioprocessing through stable molecular weight profiles, consistent mineral levels, and controlled manufacturing for dependable lot‑to‑lot performance.

  5. Spray Drying Applications In The Pharmaceutical Industry 3/10/2026

    Spray drying turns liquids into uniform powders, improving stability, solubility, flowability, and bioavailability while allowing precise control of particle traits.

  6. LNP And Liposomal Center Of Excellence 3/10/2026

    A connected development pathway supports smoother scale-up and greater consistency for LNP-based therapeutics. Explore how integrated expertise across key stages helps teams accelerate progress.

  7. Transparent Pricing In Bioanalysis: A Feature, Not A Bonus 3/9/2026

    Unclear CRO pricing leaves small biotechs vulnerable to budget swings. Transparent, itemized costs cut financial risk, sharpen planning, and build trust by setting expectations from the start.

  8. How Smaller Biotechs Are Rethinking CRO Relationships Post-Pandemic 3/9/2026

    Smaller biotechs are rethinking CRO partnerships, valuing speed, scientific access, flexibility, and transparent pricing over scale — driven by pandemic lessons and a sharper focus on operational fit.

  9. 5 QMS Blind Spots You Should Know About 3/6/2026

    Companies often underestimate the complexity of standing up an eQMS. These are five of the most common issues that lead to regulatory and GMP exposure risk.

  10. Translating Stem Cell Programs To GMP 3/4/2026

    A detailed exploration of challenges in advancing stem cell programs to GMP, highlighting strategies to control variability, strengthen process design, and support reliable clinical‑stage manufacturing.